Chicago Clinical Laboratories, LTD
Chicago Clinical Laboratories, LTD was paid $11.59M by Medicaid between Jan 2018 and Dec 2024, across 130 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 19% of everything it billed.
NORTHBROOK, IL 60062
Next to other Clinical Medical Laboratory providers in Illinois
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 275,284 | $1.17M | |
| 2019 | 297,715 | $1.33M | |
| 2020 | 315,388 | $2.89M | |
| 2021 | 276,026 | $1.95M | |
| 2022 | 254,368 | $1.62M | |
| 2023 | 246,704 | $1.34M | |
| 2024incomplete | 235,994 | $1.28M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 19% | 32,169 | 13,311 | $2.25M |
| 80053 | Comprehensive metabolic panel | 11% | 184,838 | 130,639 | $1.30M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 10% | 272,314 | 173,556 | $1.21M |
| 84443 | Thyroid stimulating hormone (TSH) | 6.2% | 61,093 | 53,634 | $714K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 5.7% | 263,471 | 138,410 | $665K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.6% | 80,563 | 50,548 | $414K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.2% | 36,803 | 32,734 | $366K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.9% | 64,732 | 57,266 | $337K |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 2.7% | 134,981 | 73,270 | $308K |
| 80061 | Lipid panel | 2.5% | 66,003 | 57,842 | $293K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.7% | 11,708 | 5,220 | $192K |
| 87088 | 1.7% | 30,697 | 26,051 | $191K |
118 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.6% | 30,760 | $182K |
| 87186 | 1.5% | 24,539 | $176K | |
| 80050 | General health panel | 1.5% | 4,388 | $168K |
| 85610 | 1.4% | 62,095 | $165K | |
| 80164 | 1.4% | 23,366 | $159K | |
| 82607 | 1.3% | 18,204 | $150K | |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 46,243 | $125K |
| 82746 | 1.0% | 14,040 | $116K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,723 | $111K |
| 83735 | <1% | 21,566 | $108K | |
| 83880 | <1% | 6,494 | $99K | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 109,211 | $95K |
| 84439 | <1% | 13,517 | $88K | |
| 80202 | <1% | 7,029 | $73K | |
| 84153 | <1% | 6,654 | $70K | |
| 85027 | <1% | 16,489 | $69K | |
| 80185 | <1% | 7,486 | $68K | |
| 80177 | <1% | 9,600 | $65K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,582 | $64K |
| 82140 | <1% | 10,695 | $64K | |
| 81001 | <1% | 36,529 | $64K | |
| 82728 | <1% | 7,665 | $45K | |
| 87040 | <1% | 3,744 | $44K | |
| 86140 | <1% | 12,558 | $43K | |
| 87631 | <1% | 525 | $37K | |
| 83540 | <1% | 8,008 | $35K | |
| 83970 | <1% | 1,667 | $34K | |
| 85651 | <1% | 10,542 | $34K | |
| 83550 | <1% | 6,042 | $33K | |
| 80178 | <1% | 6,482 | $32K | |
| 87077 | <1% | 15,642 | $32K | |
| 84100 | <1% | 8,984 | $30K | |
| 87449 | <1% | 2,967 | $30K | |
| 84145 | <1% | 1,963 | $28K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 126 | $28K |
| 87324 | <1% | 2,810 | $27K | |
| 84480 | <1% | 3,541 | $25K | |
| 80076 | <1% | 4,310 | $24K | |
| 82248 | <1% | 7,106 | $24K | |
| 82947 | <1% | 7,797 | $23K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 536 | $23K |
| 86480 | <1% | 475 | $21K | |
| 84134 | <1% | 3,859 | $21K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 536 | $21K |
| 80156 | <1% | 3,119 | $20K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 516 | $20K |
| 83690 | <1% | 3,988 | $19K | |
| 87070 | <1% | 4,563 | $18K | |
| 84436 | <1% | 4,371 | $18K | |
| 84481 | <1% | 2,073 | $17K | |
| 86706 | <1% | 1,494 | $17K | |
| 85379 | <1% | 2,821 | $17K | |
| 82150 | <1% | 3,591 | $17K | |
| 86803 | <1% | 960 | $13K | |
| 80159 | <1% | 1,916 | $13K | |
| 82550 | <1% | 3,139 | $12K | |
| 80069 | <1% | 2,532 | $11K | |
| 82565 | <1% | 3,890 | $10K | |
| 82570 | <1% | 2,770 | $10K | |
| 84550 | <1% | 3,326 | $9K | |
| 87340 | <1% | 769 | $8K | |
| 84132 | <1% | 2,673 | $8K | |
| 80162 | <1% | 1,648 | $8K | |
| 86592 | <1% | 2,011 | $7K | |
| 80074 | <1% | 229 | $7K | |
| 80175 | <1% | 597 | $6K | |
| 87184 | <1% | 1,193 | $6K | |
| 82043 | <1% | 1,930 | $6K | |
| 80184 | <1% | 837 | $5K | |
| 85730 | <1% | 1,131 | $5K | |
| 84146 | <1% | 326 | $4K | |
| 84520 | <1% | 1,924 | $4K | |
| 83615 | <1% | 923 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 73 | $3K |
| 82270 | <1% | 1,417 | $3K | |
| 87493 | <1% | 90 | $3K | |
| 87902 | <1% | 15 | $3K | |
| 85004 | <1% | 1,140 | $3K | |
| 84703 | <1% | 393 | $3K | |
| 80183 | <1% | 305 | $2K | |
| 87536 | <1% | 29 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 191 | $2K |
| 87081 | <1% | 467 | $2K | |
| 82310 | <1% | 627 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 34 | $2K |
| 84460 | <1% | 529 | $2K | |
| 87632 | <1% | 17 | $2K | |
| 80051 | <1% | 426 | $1K | |
| 82040 | <1% | 482 | $1K | |
| 83789 | <1% | 94 | $1K | |
| 82272 | <1% | 738 | $940.24 | |
| 84450 | <1% | 343 | $913.32 | |
| 83655 | <1% | 81 | $855.19 | |
| 82374 | <1% | 369 | $847.60 | |
| 84295 | <1% | 391 | $836.07 | |
| 84075 | <1% | 287 | $761.59 | |
| 82435 | <1% | 372 | $752.48 | |
| 82247 | <1% | 287 | $729.79 | |
| 87506 | <1% | 12 | $700.85 | |
| 84156 | <1% | 315 | $578.70 | |
| 85044 | <1% | 245 | $573.09 | |
| 84155 | <1% | 288 | $548.26 | |
| 86765 | <1% | 53 | $482.72 | |
| 80201 | <1% | 41 | $408.18 | |
| 86361 | <1% | 41 | $382.63 | |
| 84484 | <1% | 61 | $379.56 | |
| 82652 | <1% | 14 | $369.62 | |
| 83718 | <1% | 93 | $357.53 | |
| 86038 | <1% | 30 | $343.61 | |
| 84478 | <1% | 101 | $279.08 | |
| 82465 | <1% | 96 | $203.28 | |
| 84702 | <1% | 20 | $161.51 | |
| 84152 | <1% | 13 | $141.31 | |
| 85007 | <1% | 43 | $123.60 | |
| 81000 | <1% | 49 | $103.33 | |
| 82180 | <1% | 16 | $75.69 | |
| 86430 | <1% | 12 | $49.09 | |
| 82378 | <1% | 12 | $40.91 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.